Preoperative Concurrent Chemoradiotherapy for Stage IIIA Non-Small Cell Lung Cancer

• Published in: Acta oncologica Vol. 40; no. 5; pp. 588 - 592
• Main Author: Yong Chan Ahn, Keunchil Park, Dae Yong Kim, Kwan Min Kim, Jhingook Kim, Young Mog Shim, Kyung Soo Lee, Joungho Han, Ho Joong Kim, O Jung Kwon, Do Hoon Lim, Young Joo Noh, Jeong Eun Lee, Seung Jae Huh
• Format: Journal Article
• Language: English
• Published: Basingstoke Informa UK Ltd 2001; Taylor & Francis
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - radiotherapy; Carcinoma, Non-Small-Cell Lung - surgery; Carcinoma, Non-Small-Cell Lung - therapy; Chemotherapy, Adjuvant - adverse effects; Cisplatin - administration & dosage; Cisplatin - adverse effects; Combined Modality Therapy; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Esophagitis - etiology; Etoposide - administration & dosage; Etoposide - adverse effects; Female; Hematologic Diseases - etiology; Humans; Life Tables; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - radiotherapy; Lung Neoplasms - surgery; Lung Neoplasms - therapy; Lymph Node Excision; Lymphatic Metastasis; Male; Medical sciences; Middle Aged; Neoplasm Staging; Pharmacology. Drug treatments; Pneumonectomy; Preoperative Care; Prospective Studies; Radiation Injuries - etiology; Radioisotope Teletherapy - adverse effects; Radiotherapy, Adjuvant - adverse effects; Survival Analysis; Survival Rate; Treatment Outcome; Antineoplastic agent; Prognosis; Bronchopulmonary; Neoadjuvant treatment; Isomerases; Surgery; Bronchus disease; Complication; Advanced stage; Antimitotic; Non small cell carcinoma; Platinum II Complexes; Human; Lung disease; DNA topoisomerase (ATP-hydrolysing); Drug combination; Respiratory disease; Enzyme; Treatment efficiency; Etoposide; Enzyme inhibitor; Malignant tumor; Radiotherapy; Cisplatin; Podophyllotoxine derivatives; Alkylating agent; Chemotherapy; Combined treatment; Preoperative
• ISSN: 0284-186X; 1651-226X
• DOI: 10.1080/028418601750444123

Thirty-one patients with stage IIIA non-small cell lung cancer (NSCLC) were treated with preoperative concurrent chemoradiotherapy (CCRT) followed by surgery. The treatment protocol could not be completed in eight patients. The acute hematologic toxicities of grade III or IV occurred in 48.4% (15/31) after the first chemotherapy cycle, and in 39.1% (9/23) after the second cycle. The most common non-hematologic toxicity was radiation esophagitis. Surgery was attempted in 23 patients and successful in 22 patients (resection rate = 71.0%). Pathologic complete response and down-staging were achieved in 13.6% (3/22) and 68.2% (15/22). The median survival period, 2-year overall survival, local control and disease-free survival rates of all 31 patients and of 22 patients who underwent surgery were 19 months, 37.2%, 49.1%, 35.5%, and 19 months, 43.2%, 51.8%, 25.6%, respectively. On the basis of our observations, preoperative CCRT followed by surgery for stage IIIA NSCLC has resulted in outcomes comparable with those in previous reports.